Normal and pathological brain aging: A physiopathological continuum or an involutive duality;Envejecimiento cerebral normal y patológico: Continuum fisiopatológico o dualidad de procesos involutivos

Anales de la Real Academia Nacional de Farmacia

Volumn 80, Issue 3, 2014, Pages 500-539

  Toledano, Adolfo ^a,b   Álvarez, María Isabel ^a   Toledano Díaz, Adolfo ^c  

^a CSIC   (Spain)

^b Real Academia Nacional de Farmacia   (Spain)

^c INIA   (Spain)

Author keywords

Alzheimer's Disease; Continuum; Normal brain senility; Pathological brain senility

Indexed keywords

AGING; ALZHEIMER DISEASE; ARTICLE; HUMAN; NEUROIMAGING; PATHOPHYSIOLOGY; SENILITY;

EID: 84929992130     PISSN: 00340634     EISSN: 1697428X     Source Type: Journal    
DOI: None     Document Type: Article

References (120)

1. Population Reference Bureau. Cuadro de datos de la población mundial 2012. http://www.prb.org/pdf12/2012-population-data-sheet-spanish.pdf
2. World Health Organization, Alzheimer's Disease International. Dementia: a public health priority. WHO (OMS); Ginebra, 2012; p 12.
3. Plassman, B.L.; Langa, K.M.; Fisher, G.G.; Heeringa, S.G.; Weir, D.R.; Ofstedal, M.B.; Burke, J.R.; Hurd, M.D.; Potter, G.G.; Rodgers, W.L.; Steffens, D.C.; Willis, R.J.; Wallace, R.B. Prevalence of Dementia in the United States: The Aging, Demographics, and Memory Study. Neuroepidemiology 29, 125-132 (2007).
4. Thies, W.; Bleiler, L. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimer's Dement, 9, 208-245 (2013).
5. Dubois, B.; Feldman, H. H,; Jacova, C.; Dekosky, S. T.; Barberger-Gateau, P.; Cummings, J.; Delacourte, A.; Galasko, D.; Gauthier, S.; Jicha, G.; Meguro, K.; O'brien, J.; Pasquier, F.; Robert, P.; Rossor, M.; Salloway, S.; Stern, Y.; Visser, P. J. Scheltens P. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746 (2007).
6. Dubois, B.; Feldman, H. H.; Jacova, C.; Cummings, J. L.; Dekosky, S. T.; Barberger-Gateau, P.; Delacourte, A.; Frisoni, G.; Fox, N. C.; Galasko, D.; Gauthier, S.; Hampel, H.; Jicha, G. A.; Meguro, K.; O'Brien, J.; Pasquier, F.; Robert, P.; Rossor, M.; Salloway, S.; Sarazin, M.; de Souza, L. C.; Stern, Y.; Visser, P. J.; Scheltens, P. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol, 9, 1118-1127 (2010).
7. Lim YY, Maruff P, Pietrzak RH, Ellis KA, Darby D, Ames D, Harrington K, Martins RN, Masters CL, Szoeke C, Savage G, Villemagne VL, Rowe CC; AIBL Research Group. Aβ and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimer's Dement (en prensa) (Feb 28. doi: S1552-5260(13)02939-7) (2014).
8. Li, S.; Okonkwo, O.; Albert, M.; Wang, M. C. Variation in variables that predict progression from MCI to AD dementia over duration of follow-up. Am J Alzheimers Dis 2, 12-28 (2013).
9. Barnes, D.E.; Cenzer, I.S.; Yaffe, K.; Ritchie, C.S.; Lee, S. J. Alzheimer's Disease Neuroimaging Initiative; A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease. Alzheimers Dement. 2014 (Feb 1. doi: S1552-5260(13)02941-5) (2014)
10. Castellani, R.J.; Perry, G. The complexities of the pathology-pathogenesis relationship in Alzheimer disease. Biochem Pharmacol (en prensa). doi: 10.1016/j.bcp.2014.01.009 (2014).
11. Mucke, L.; Selkoe, D. J. Neurotoxicity of amyloid β-protein: synaptic and network Dysfunction; Cold Spring Harb Perspect Med; 2(7):a006338. doi: 10.1101/cshperspect.a006338 (2012).
12. Swerdlow, R. H. Alzheimer's disease pathologic cascades: who comes first, what drives what. Neurotox Res 22, 182-194 (2012).
13. De Pedro-Cuesta, J.; Virués-Ortega, J.; Vega, S.; Seijo-Martínez, M.; Saz, P.; Rodríguez, F.; Rodríguez-Laso, A.; Reñé, R.; de las Heras, S. P.; Mateos, R.; Martínez-Martín, P.; Manubens, J. M.; Mahillo-Fernandez, I.; López-Pousa, S.; Lobo, A.; Reglà, J.L.; Gascón, J.; García, F. J.; Fernández-Martínez, M.; Boix, R.; Bermejo-Pareja, F.; Bergareche, A.; Benito-León, J.; de Arce, A.; del Barrio, J. L. 2009. Prevalence of dementia and major dementia subtypes in Spanish populations: a reanalysis of dementia prevalence surveys, 1990-2008. BMC Neurol. 9:55. doi: 10.1186/1471-2377-9-55.
14. Marín-Padilla, M. The Human Brain: Prenatal Development and Structure. Springer, Heidelberg, 2011.
15. Marín-Padilla, M. The mammalian neocortex new pyramidal neuron: a new conception. Front Neuroanat, 7, 51-63 (doi: 10.3389/fnana.2013.00051) (2014).
16. Ramón y Cajal, S. (1911). Histologie du systéme nerveux de l'homme et des vertebrés. Maloine, París, (1911) (reedición CSIC, Madrid, 1952).
17. Basak, O., Taylor, V. Stem cells of the adult mammalian brain and their niche. Cell. Mol Life Sci 66, 1057-1072 (2009).
18. Sala, C.; Segal, M. Dendritic spines: the locus of structural and functional plasticity. Physiol Rev 94(1), 141-88 (2014).
19. Vitureira, N.; Goda, Y. Cell biology in neuroscience: the interplay between Hebbian and homeostatic synaptic plasticity. J Cell Biol 203, 175-186 (2013)
20. Bhalla, U. S. Multiscale Modeling and Synaptic Plasticity. Prog Mol Biol Trans Sci 123, 351-386 (2014).
21. Toledano, A. Mecanismos de adaptación en el Sistema Nervioso. Su importancia en la patología y la terapéutica. Anal Real Acad Farm 65, 693-767 (1999).
22. Frol'kis, V.V.; Bezrukov, V.V. Aging of the central nervous system. Hum Physiol 4, 478-499 (1979).
23. Connor, J.R. jr.; Diamond, M.C.; Johnson A.R.E. Aging and Environmental Influences on two types of dendritic Spines in the rat occipital cortex. Experimental Neurology 70, 371-379 (1980)
24. Buell, S.; Coleman, P. Dendritic growth in the aged human brain and failure of growth in senile dementia. Science 206, 854-856 (1979).
25. Organización Mundial de la Salud. Clasificación Internacional de las Enfermedades, 10o edición. (CIE-10). Capítulo V. Trastornos mentales y del comportamiento. Descripciones clínicas y pautas para el diagnóstico. Meditor, Madrid, 1993, p 63.
26. Alzheimer, A. Über eine eigenartige erkrankung der hirnrinde. Allg Z Psychiat 64, 146-148 (1907).
27. Kraepelin, E . Psychiatrie: Ein Lehrbuch für Studierende und Ärzte. II. Band. Barth Verlag, Leipzig, 1910, p 21
28. American Psychiatric Association. Manual diagnóstico y estadístico de los trastornos mentales DSM IV. Masson, Barcelona, 2002, p 149.
29. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. DSM-5. ISBN 978-0-89042-554-1 (en prensa), 2015.
30. Khachaturian; ZS. Diagnosis of Alzheimer's Disease. Arch Neurol 42, 1097-1105 (1985).
31. Mirra, S. S.; Heyman, A.; Mckeel, D.; Sumi, S. M.; Crain, B. J.; Brownlee, L. M.; Vogel, F. S.; Hughes, J. P.; Van Belle, G.; Berg, L. The Consortium to establish a registry for Alzheimer's disease (CERAD); Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486 (1991).
32. Chételat, G.; Villemagne, V. L.; Pike, K. E.; Baron, J. C.; Bourgeat, P.; Jones, G.; Faux, N.G.; Ellis, K. A.; Salvado, O.; Szoeke, C.; Martins, R. N.; Ames, D.; Masters, C. L.; Rowe, C. C. Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain 133, 3349-3358 (2010).
33. Leuba, G.; Saini, K.; Zimmermann, V.; Giannakopoulos, P.; Bouras, C. Mild amyloid pathology in the primary visual system of nonagenarians and centenarians. Dement Geriatr Cogn Disord 12, 146-152 (2001).
34. Tolnay, M.; Calhoun, M.; Pham, H. C.; Egensperger, R.; Probst. A Low amyloid (Abeta) plaque load and relative predominance of diffuse plaques distinguish argyrophilic grain disease from Alzheimer's disease. Neuropathol Appl Neurobiol 25, 295-305 (1999).
35. Ince, P.; Irving, D.; MacArthur, F.; Perry, R. H. Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly control patients. J Neurol Sci. 106,142-152 (1991).
36. Mesulam, M. M.; Weintraub, S.; Rogalski, E. J.; Wieneke, C.; Geula, C.; Bigio, E. H. Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primaryprogressive aphasia. Brain (en prensa) (2014).
37. Panza, F.; Frisardi, V.; Capurso, C.; D'Introno, A.; Colacicco, A. M.; Imbimbo, B. P.; Santamato, A.; Vendemiale, G.; Seripa, D.; Pilotto, A.; Capurso, A.; Solfrizzi, V.; Late-life depression, mild cognitive impairment, and dementia: possible continuum? Am J Geriatr Psychiatr 18, 98-116 (2010).
38. Wadsworth, L.P.; Lorius, N.; Donovan, N.J.; Locascio, J. J.; Rentz, D. M.; Johnson, K. A.; Sperling, R. A.; Marshall, G.A. Neuropsychiatric symptoms and global functional impairment along the Alzheimer's continuum. Dement Geriatr Cogn Disord 34, 96-111 (2012).
39. Zhang, M.; Wang, H.; Li, T.; Yu, X. Prevalence of neuropsychiatric symptoms across the declining memory continuum: an observational study in a memory clinic setting. Dement Geriatr Cogn Dis Extra 2, 200-208 (2012).
40. Rami, L.; Fortea, J.; Bosch, B.; Solé-Padullés, C.; Lladó, A.; Iranzo, A.; Sánchez-Valle, R.; Molinuevo, J. L. Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. J Alz Dis 23, 319-26 (2011).
41. Hyman, B. T.; Phelps, C. H.; Beach, T. G.; Bigio, E. H.; Cairns, N. J.; Carrillo, M. C.; Dickson, D. W.; Duyckaerts, C.; Frosch, M. P.; Masliah, E.; Mirra, S. S.; Nelson, P. T.; Schneider, J.A.; Thal, D.R.; Thies, B.; Trojanowski, J. Q.; Vinters, H.V., Montine, T.J. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. Dis. 8, 1-13 (2012).
42. Town, T.; Nikolic, V.; Tan, J. The microglial "activation" continuum: from innate to adaptive responses. J Neuroinflammation 31, 2-24 (2005).
43. Thal, D. R.; Rüb, U.; Orantes, M.; Braak, H. Phases of Abeta deposition in the human brain and its relevance for the development of AD. Neurology 58, 1791-1800 (2002).
44. Braak, H.; Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259 (1991).
45. Nelson, P. T.; Alafuzoff, I.; Bigio, E. H.; Bouras, C.; Braakm, H.; Cairns, N. J:, Castellani, R. J.; Crain, B. J.; Davies, P.; Del Tredici, K.; Duyckaerts, C.; Frosch, M. P.; Haroutunian, V.; HofPR.; Hulette, C.M.; Hyman, B.T.; Iwatsubo, T.; Jellinger, K. A.; Jicha, G. A.; Kövari, E.; Kukull, W. A.; Leverenz, J. B.; Love, S.; Mackenzie, I. R.; Mann, D. M.; Masliah, E.; McKee, A. C.; Montine, T. J.; Morris, J. C.; Schneider, J. A.; Sonnen, J. A.; Thal, D. R.; Trojanowski, J. Q.; Troncoso, J. C.; Wisniewski, T.; Woltjer, R. L.; Beach, T. G. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71, 362-381 (2012).
46. Josephs, K. A.; Whitwell, J. L.; Ahmed, Z.; Shiung, M. M.; Weigand, S. D.; Knopman, D. S.; Boeve, B. F.; Parisi, J. E.; Petersen, R. C.; Dickson, D. W.; Jack, C.R.; Jr. Beta-amyloid burden is not associated with rates of brain atrophy. Ann Neurol 63, 204-12 (2008).
47. Toga, A. W. The clinical value of large neuroimaging data sets in Alzheimer's disease. Neuroimaging Clin N Am 22, 107-118 (2012).
48. Wirth, M.; Villeneuve, S.; Haase, C. M.; Madison, C. M.; Oh, H.; Landau, S. M.; Rabinovici, G. D.; Jagust, W. J. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol. 70,1512-1519 (2013)
49. Panza, F.; Frisardi, V.; Capurso, C.; D'Introno, A.; Colacicco, A. M.; Chiloiro, R.; Dellegrazie; F.; Di Palo, A.; Capurso, A.; Solfrizzi, V. Effect of donepezil on the continuum of depressive symptoms, mild cognitive impairment, and progression to dementia. J Am Geriatr Soc 58, 389-390 (2010).
50. Wright, L. K.; Litaker, M.; Laraia, M. T.; DeAndrade, S. Continuum of care for Alzheimer's disease: a nurse education and counseling program. Issues Ment Health Nurs 22, 231-252 (2001).
51. Cohen, A. D.; Rabinovici, G. D.; Mathis, C. A.; Jagust, W. J.; Klunk, W. E.; Ikonomovic, M. D. Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol 64, 27-81 (2012).
52. Armstrong, R. A. The interface between Alzheimer's disease, normal aging, and related disorders. Curr Aging Sci 1, 122-132 (2008).
53. Saunders, A. M.; Strittmatter, W. J.; Schmechel, D.; George-Hyslop, P. H.; Pericak-Vance, M. A.; Joo, S. H.; Rosi, B. L.; Gusella, J. F.; Crapper-MacLachlan, D. R.; Alberts, M. J. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472 (1993).
54. Ringman, J. M.; Coppola, G. New genes and new insights from old genes: update on Alzheimer disease. Continuum (Minneap Minn) 19, 358-71 (2013).
55. Serrano-Pozo, A.; Qian, J.; Monsell, S. E.; Frosch, M. P.; Betensky, R.A.; Hyman, B. T. Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol. 72,1182-1192 (2013).
56. Pappolla, M. A. La Neuropatología y la Biología Molecular de la Enfermedad de Alzheimer. En:. Neuropathología. Diagnóstico y Clínica. Cruz-Sánchez F.F., Ed.; Edimsa, Barcelona, 2000; p 543.
57. Penke, B.; Tóth, A. M.; Földi, I.; Szu'cs, M.; Janáky, T. Intraneuronal β-amyloid and its interactions with proteins and subcellular organelles. Electrophoresis 33, 3608-3616 (2012).
58. Delacourte, A. General and dramatic glial reaction in Alzheimer brains. Neurology 40, 33-37 (1990)
59. Dickson; C., Vickers, J. C. The morphological phenotype of b-amyloid plaques and associated neuritic changes in Alzheimer's. Neuroscience 105, 99-107 (2001).
60. Wegiel, J.; Wang, K. C.; Tarnawski, M.; Lach, B. Microglia cells are the driving force in fibrillar plaque formation, whereas astrocytes are a leading factor in plague degradation. Acta Neuropathol 100, 356-364 (2000).
61. Bartus, R. T.; Dean, R. L.; 3rd, Beer, B. Lippa AS The cholinergic hypothesis of geriatric memory dysfunction. Science 30, 217(4558):408-14 (1982).
62. Mann, D. M.; Yates, P. O.; Marcyniuk, B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol 10, 185-207 (1984).
63. Mecocci, P. Oxidative stress in mild cognitive impairment and Alzheimer disease: a continuum. J Alzheimers Dis. 2004 Apr;6(2):159-63.
64. Nixon, R. A.; Yang, D. S.; Lee, J. H. Neurodegenerative lysosomal disorders: a continuum from development to late age. Autophagy 4, 590-9 (2008).
65. Toledano, A.; Álvarez, MI.; Rivas, L.; Lacruz, C.; Martínez-Rodríguez, R. Amyloid precursor protein in the cerebellar cortex of Alzheimer 's disease patients devoid of cerebellar β-amyloid deposits. Immunocytochemical study of five cases. J Neural Trans 106, 1151-1169 (1999).
66. Toledano, A. Hypotheses concerning the aetiology of the Alzheimer's disease. Pharmacopsychiat 21, 17-25 (1988).
67. Toledano, A.; Bentura, M. Pyritinol facilitates the recovery of cortical cholinergic deficits caused by nucleus basalis lesions J Neural Transm [P-D Section] 7, 195-209 (1994).
68. Drachman, D. A.; Leavitt, J. Human memory and the cholinergic system: relationship to aging? Arch Neurol 30, 113-121 (1974).
69. Coyle, J. T.; Price, D. L.; De Long, M. R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219, 1184-1190 (1983).
70. Schneider, L. S. Alzheimer disease pharmacologic treatment and treatment research. Continuum (Minneap Minn). 19, 339-357 (2013).
71. Van Hoesen, G. W.; Augustinack, J. C.; Dierking, J.; Redman, S. J.; Thangavel, R. The parahippocampal gyrus in Alzheimer's disease. Clinical and preclinical neuroanatomical correlates. Ann N Y Acad Sci 911, 254-274 (2000).
72. de Toledo-Morrell, L.; Goncharova, I.; Dickerson, B.; Wilson, R. S.; Bennett, D. A. From healthy aging to early Alzheimer's disease: in vivo detection of entorhinal cortex atrophy. Ann N Y Acad Sci 911, 240-53 (2000).
73. Stricker, N. H.;(1), Chang, Y. L.; Fennema-Notestine, C.; Delano-Wood, L.; Salmon, D. P.; Bondi, M. W.; Dale, A. M. Alzheimer's Disease Neuroimaging Initiative. Distinct profiles of brain and cognitive changes in the very old with Alzheimer disease. Neurology 77, 713-21 (2011).
74. Villain, N.; Chételat, G.; Grassiot, B.; Bourgeat, P.; Jones, G.; Ellis, K. A.; Ames, D.; Martins, R. N.; Eustache, F.; Salvado, O.; Masters, C. L.; Rowe, C. C.; Villemagne, V. L. AIBL Research Group. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. Brain 135, 2126-2139 (2012).
75. Okello, A.; Koivunen, J.; Edison, P.; Archer, H. A.; Turkheimer, F. E.; Någren, K.; Bullock, R., Walker, Z.; Kennedy, A.; Fox, N. C.; Rossor, M. N.; Rinne, J. O.; Brooks, D. J. Conversion ofamyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73, 754-760 (2009).
76. Toledano, A.; Álvarez, M. I.; López-Rodríguez, A. B.; Toledano-Díaz, A.; Fernández-Verdecia, C. I. Does Alzheimer's disease exist in all primates? Alzheimer pathology in non-human primates and its pathophysiological implications (I). Neurologia 27, 354-69 (2012) [también versión en español]
77. Toledano, A.; Álvarez, M. I.; López-Rodríguez, A. B.; Toledano-Díaz, A.; Fernández-Verdecia, C. I. Does Alzheimer's disease exist in all primates? Alzheimer pathology in non-human primates and its pathophysiological implications (II) Neurologia. 29, 42-55 (2014) [también versión en español]
78. Hardy, J.; Selkoe, D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 19, 353-356 (2002).
79. Toledano, A.; Álvarez, M. I.; Carmona, P.; Toledano-Díaz, A.; Fernández-Verdecia, C. I. Alzheimer pathology in non-human primates and its pathophysiological implications. En: Primates. Classification, evolution and behavior. Hughes E. F.; Hill M. Eds. Nova Sciences Pub, New York, 2012; p 71-110.
80. Bons, N.; Rieger, F.; Prudhomme, D.; Fisher, A.; Krause, K. H. Microcebus murinus: a useful primate model for human cerebral aging and Alzheimer's disease? Genes Brain Behav 5, 120-130 (2006).
81. Voytko, M. L.; Tinker, G. P. Cognitive function and its neural mechanism in nonhuman primate models of aging Alzheimer's diseases, and menopause. Front Biosci 9, 1899-1914 (2004).
82. McGuire, M. T. The St Kitts vervet (Cercopithecus aethiops). J Med Primatol 3, 285-297 (1974).
83. Lemere, C. A.; Beierschmitt, A.; Iglesias, M.; Spooner, E. T.; Bloom, J.K.; Leverone, J. F. Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a nonhuman primate, the Caribbean vervet. Am J Pathol 165, 83-97 (2004).
84. Rosen, R. F.; Farberg, A. S.; Gearing, M.; Dooyema, J.; Long, P. M.; Anderson, D. C. Tauopathy with paired helical filaments in an aged chimpanzee. J Comp Neurol 509, 259-270 (2008).
85. LaFerla, F. M.; Green, K. N. Animal models of Alzheimer disease. Cold Spring Harb Perspect Med, 2 (11), a006320. doi: 10.1101/cshperspect.a006320 (2012).
86. Scheffler, K.; Stenzel, J.; Krohn, M.; Lange, C.; Hofrichter, J.; Schumacher, T.; Brüning, T.; Plath, A. S.; Walker, L.; Pahnke, J. Determination of spatial and temporal distribution of microglia by 230nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP/PS1 mouse model of Alzheimer's disease. Curr Alzheimer Res 8,781-788 (2011).
87. Bales, K.R. The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. Expert Opin Drug Discov. 7, 281-297 (2012).
88. Howlett, D. R. APP transgenic mice and their application to drug discovery. Histol Histopathol 26, 1611-1632 (2011).
89. Boche, D.; Denham, N.; Holmes, C.; Nicoll, J. A. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol 120, 369-384 (2010).
90. Fjell, A.; McEvoy, M.; Holland, L.; D.; Dale, A. M.; Walhovda, K. B. The Alzheimer's disease Neuroimaging Initiative. What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. Prog Neurobiol (en prensa) (2014). http://dx.doi.org/10.1016/j.pneurobio.2014.02.004.
91. Fischer, F. U.; Wolf, D.; Scheurich, A.; Fellgiebel, A. Association of structural global brain network properties with intelligence in normal aging. PLoS One 22, 9 (2014). doi: 10.1371/journal.pone.0086258.
92. Roussotte, F. F.; Gutman, B. A.; Madsen, S. K.; Colby, J. B.; Narr, K. L.; Thompson, P. M.; Alzheimer's disease Neuroimaging Initiative (ADNI). The apolipoprotein E epsilon 4 allele is associated with ventricular expansion rate and surface morphology in dementia and normal aging. Neurobiol Aging 35, 1309-1317 (2014).
93. Mosconi, L. Glucose metabolism in normal aging and Alzheimer's disease: Methodological and physiological considerations for PET studies. Clin Trans Imaging 1, doi: 10.1007/s40336-013-0026-y (2013).
94. Nugent, S.; Tremblay, S.; Chen, K. W.; Ayutyanont, N.; Roontiva, A.; Castellano, C. A.; Fortier, M.; Roy, M.; Courchesne-Loyer, A.; Bocti, C.; Lepage, M.; Turcotte, E.; Fulop, T.; Reiman, E. M.; Cunnane, S. C. Brain glucose and acetoacetate metabolism: a comparison of young and older adults. Neurobiol Aging 35, 1386-1395 (2014).
95. Kövari, E.; Herrmann, F. R.; Bouras, C.; Gold, G. Amyloid deposition is decreasing in aging brains: an autopsy study of 1,599 older people. Neurology 28, 326-331 (2014)
96. Da, X.; Toledo, J. B.; Zee, J.; Wolk, D. A.; Xie, S. X.; Ou, Y.; Shacklett, A.; Parmpi, P.; Shaw, L.; Trojanowski, J. Q.; Davatzikos, C. Alzheimer's Neuroimaging Initiative. Integration and relative value of biomarkers for prediction of MCI to AD progression: Spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers. Neuroimage Clin. 28, 164-173 (2013)
97. Madhyastha, T. M.; Grabowski, T. J. Age-related differences in the dynamic architecture of intrinsic networks. Brain Connect 30, (en prensa) (2014).
98. Toledano, A.; Álvarez M. I.; Toledano-Díaz, A. Multiple neuronal and glial mechanisms can be involved in the response to the activation of nicotinic receptors. A. In: Horizons in Neuroscience Research. Volume 3 Neural Transmissions: Characteristics, Mechanisms and Malfunctioning, Costa, A. Villalba, E. (Eds). Nova Science Publishers, Inc.; Hauppauge, NY, pp 1-34 (2011).
99. Wolf, D.; Grothe, M.; Fischer, F. U.; Heinsen, H.; Kilimann, I.; Teipel, S.; Fellgiebel, A. Association of basal forebrain volumes and cognition in normal aging. Neuropsychologia 53, 54-63 (2014).
100. Wirth, M.; Villeneuve, S.; Haase, C. M.; Madison, C. M.; Oh, H.; Landau, S. M.; Rabinovici, G. D.; Jagust, W. J. Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people. JAMA Neurol 70, 1512-1519 (2013).
101. Jack, C.R Jr.; Wiste, H. J.; Weigand, S. D.; Knopman, D. S.; Lowe, V.; Vemuri, P.; Mielke, M. M.; Jones, D.T.; Senjem, M. L.; Gunter, J. L.; Gregg, B. E.; Pankratz, V. S.; Petersen, R. C. Amyloidfirst and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 12, 1732-1740 (2013).
102. Gold, P. E.; Newman, L. A.; Scavuzzo, C. J,; Korol, D. L. Modulation of multiple memory systems: from neurotransmitters to metabolic substrates. Hippocampus 23, 1053-1065 (2013).
103. Negash, S.; Wilson, R. S.; Leurgans, S. E.; Wolk, D. A.; Schneider, J. A.; Buchman, A. S.; Bennett, D. A.; Arnold, S. E. Resilient brain aging: characterization of discordance between Alzheimer's disease pathology and cognition. Curr Alzheimer Res 10, 844-851 (2013).
104. Shulman, J. M.; Chen, K.; Keenan, B. T.; Chibnik, L. B.; Fleisher, A.; Thiyyagura, P.; Roontiva, A.; McCabe, C.; Patsopoulos, N. A.; Corneveaux, J. J.; Yu, L.; Huentelman, M. J.; Evans, D. A.; Schneider, J. A.; Reiman, E. M.; De Jager, P. L.; Bennett, D.A. Genetic susceptibility for Alzheimer disease neuritic plaque pathology. JAMA Neurol 1, 1150-1157 (2013).
105. Cha, J.; Jo, H. J.; Kim, H. J.; Seo, S. W.; Kim, H. S.; Yoon, U., Park, H:, Na, D. L.; Lee, J. M. Functional alteration patterns of default mode networks: comparisons of normal aging, amnestic mild cognitive impairment and Alzheimer's disease. Eur J Neurosci 37, 1916-1924 (2013).
106. Hall, C. N.; Reynell, C.; Gesslein, B.; Hamilton, N. B.; Mishra, A.; Sutherland, B. A.; O'Farrell, F. M.; Buchan, A. M.; Lauritzen, M., Attwell, D. Capillary pericytes regulate cerebral blood flow in health and disease. Nature 26, (en prensa) (2014) doi: 10.1038/nature13165.
107. Verkhratsky, A.; Rodríguez, J. J.; Parpura, V. Neuroglia in ageing and disease. Cell Tissue Res 21 (en prensa) (2014). doi: 10.1007/s00441-014-1814-z
108. Kilimann, I.; Grothe, M.; Heinsen, H.; Alho, E. J.; Grinberg, L.; Amaro, Jr. E.; Dos Santos, G. A.; da Silva, R. E.; Mitchell, A. J.; Frisoni, G. B.; Bokde, A. L.; Fellgiebel, A.; Filippi, M.; Hampel, H.; Klöppel, S.; Teipel, S. J. Subregional Basal Forebrain Atrophy in Alzheimer's Disease: A Multicenter Study. J Alzheimers Dis 6 (2014). doi:10.3233/JAD-132345
109. Scheff, S. W.; Neltner, J. H.; Nelson, P. T. Is synaptic loss a unique hallmark of Alzheimer's disease? Biochem Pharmacol. 9 (en prensa) (2014). doi: 10.1016/j.bcp.2013.12.028.
110. Lee, C. W.; Shih, Y. H.; Kuo, Y. M. Cerebrovascular pathology and amyloid plaque formation in Alzheimer's disease. Curr Alzheimer Res 11, 4-10 (2014).
111. Beason-Held, L. L.; Goh, J. O.; An, Y.; Kraut, M. A.; O'Brien, R. J.; Ferrucci, L.; Resnick, S. M. Changes in brain function occur years before the onset of cognitive impairment. J Neurosci 13, 18008-18014 (2013).
112. Wang, X.; Wang, W.; Li, L.; Perry, G.; Lee, H. G.; Zhu, X. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. Biochim Biophys Acta. (en prensa) (2013) doi: 10.1016/j.bbadis.2013.10.015.
113. Jellinger, K. A.; Attems, J. Neuropathological approaches to cerebral aging and neuroplasticity. Dialogues Clin Neurosci 15, 29-43 (2013).
114. Lefort, R.; Pozueta, J.; Shelanski, M. Cross-linking of cell surface amyloid precursor protein leads to increased β-amyloid peptide production in hippocampal neurons: implications for Alzheimer's disease. J Neurosci 32, 10674-10685 (2012).
115. Shulman, J. M.; Chibnik, L. B.; Aubin, C.; Schneider, J. A.; Bennett, D.A.; De Jager, P. L. Intermediate phenotypes identify divergent pathways to Alzheimer's disease. PLoS One 5(6), e11244 (2010). doi: 10.1371/journal.pone.0011244.
116. Oikawa, N.; Kimura, N.; Yanagisawa, K. Alzheimer-type tau pathology in advanced aged nonhuman primate brains harboring substantial amyloid deposition. Brain Res 1315, 137-149 (2010).
117. Bell, K. F.; Ducatenzeiler, A.; Ribeiro-da-Silva, A.; Duff, K.; Bennett, D. A., Cuello, A. C. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging 27, 1644-1657 (2006).
118. Arnold, S.E.; Han, L. Y.; Clark, C. M.; Grossman, M.; Trojanowski, J. Q. Quantitative neurohistological features of frontotemporal degeneration. Neurobiol Aging 21, 913-919 (2000).
119. Toledano, A.; Álvarez M. I. Lesion-induced vertebrate models of Alzheimer Dementia. En Animal models of Dementia; Deyn, P.P.; Van Dam, D. (Eds). Humana Press; Amsterdam, 210; pp 295-345.
120. Toledano, A.; Álvarez M. I.; Toledano-Díaz, A. Diversity and variability of the nicotine effects on different brain cortical regions. Therapeutic and toxicologic implications. CNS Agents Med Chem 10, 180-206 (2010).